Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CVS Caremark
Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action
Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.
UnitedHealthcare Announces Zero Cost Sharing For Insulin As Legislative Relief Faces Challenges
Private sector efforts to lower cost sharing for insulin continue but patient advocates and lawmakers still believe legislation is needed to tackle the issue in a comprehensive way.
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics
Federal Trade Commission’s ‘pro-competitive’ perspective could support conclusion that pharmacy benefit managers serve useful role in lowering drug costs, health policy expert suggests. FTC will get an earful about PBM practices, but ‘those complaints could be an indication that competition is working.’
- Other Names / Subsidiaries
- Caremark Rx Inc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.